Enzo Biochem, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kara Cannon
- Full Time Employees
- 125
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 527 Madison Avenue New York City NY United States of America 10022
- IPO Date
- Jun 12, 1980
- CIK
- 0000316253
- Website
- enzo.com
- Similar Companies
- Business
- Enzo Biochem, Inc. (ENZB) operates as a life sciences company specializing in labeling and detection technologies spanning DNA to whole cell analysis. The company provides a comprehensive portfolio of research products through its Enzo Life Sciences division, including antibodies, genomic probes, immunoassays, biochemicals, proteins, labels, dyes, cell-based assays, and kits for applications in cell biology, genomics, immunohistochemistry, small molecule chemistry, and multiomics analysis; it monetizes these proprietary technologies via global distribution sales and licensing to academic researchers, clinical researchers, biotechnology firms, pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem conducts operations in the United States and internationally, with offices in New York, Switzerland, Germany, France, the United Kingdom, and Benelux. Founded in 1976 and headquartered in Farmingdale, New York, the company maintains ISO and GMP certifications and holds over 500 patents, with products cited in more than 175,000 studies. In August 2025, Battery Ventures completed a take-private transaction acquiring Enzo Biochem for $0.70 per share in cash, delisting it from public markets to fuel accelerated innovation, R&D investment, market expansion, and strategic acquisitions in research reagents; Jason Apter joined as group CEO, supported by Battery executives on the board.
URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote - Enzo Biochem, Inc. (OTCMKTS: ENZB)
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Enzo Biochem, Inc. (OTCMKTS: ENZB)
ENZO BIOCHEM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Enzo Biochem, Inc. - ENZB
ENZB Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Enzo Biochem, Inc. Is Fair to Shareholders
Enzo Biochem Reports Third Quarter Fiscal Year 2025 Results
Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
The Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
Enzo Biochem Reports Second Quarter Fiscal Year 2025 Results
Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules
ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges
Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update
ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands
Enzo Biochem Reports Fourth Quarter and Fiscal Year 2024 Results and Announces Cash Dividend
Enzo Biochem to pay $4.5 mln for failing to safeguard patient data
Enzo Biochem: Is This Time Finally Different?
Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation
Enzo Biochem (ENZ) Q3 Earnings Improve Y/Y, Gross Margin Up
Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update
Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update